Bayer Links
Investor RelationsNews Overview
January 7, 2009
December 8, 2008
Venous Blood Clot Prevention after Knee or Hip Replacement Surgery:
Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program
Pooled Analysis of RECORD1-4 Trials Confirms Significant Benefit in Clinical Outcomes for Patients Treated with Xarelto / RECORD4 Study Demonstrates Xarelto is the Only Oral Anticoagulant to Show Clinical Benefit in Head-to-Head Comparison Against U.S.-Approved Regimen of Enoxaparin » more
Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program
Pooled Analysis of RECORD1-4 Trials Confirms Significant Benefit in Clinical Outcomes for Patients Treated with Xarelto / RECORD4 Study Demonstrates Xarelto is the Only Oral Anticoagulant to Show Clinical Benefit in Head-to-Head Comparison Against U.S.-Approved Regimen of Enoxaparin » more
December 5, 2008
November 25, 2008
Bayer Healthcare llc Reaches Settlement with U.S. Department of Justice on Investigation into former Diabetes Care Marketing Programs
Corporate Integrity Agreement to cover Bayer HealthCare Diabetes Care, Bayer HealthCare Pharmaceuticals, Medrad (including Possis), Intendis and Viterion TeleHealthcare » more
Corporate Integrity Agreement to cover Bayer HealthCare Diabetes Care, Bayer HealthCare Pharmaceuticals, Medrad (including Possis), Intendis and Viterion TeleHealthcare » more
November 11, 2008
Bayer CropScience CEO opens new rice development center in Thailand
Professor Berschauer: “Enabling a second green revolution in Asia with new, high-yielding rice varieties”
Rice seed production in Asia to be expanded substantially by 2017 » more
Professor Berschauer: “Enabling a second green revolution in Asia with new, high-yielding rice varieties”
Rice seed production in Asia to be expanded substantially by 2017 » more
November 3, 2008
Bayer CropScience plans to invest EUR 15 million in Nunhems’ Parma site in the U.S.
Further milestone in expanding seeds business » more
1:14 min.
Further milestone in expanding seeds business » more
1:14 min.October 29, 2008
News Conference Call for the Third Quarter of 2008
Address by Werner Wenning
Chairman of the Board of Management » more
Address by Werner Wenning
Chairman of the Board of Management » more
October 29, 2008
Interim report for the third quarter of 2008:
Bayer optimistic about future business trend
Sales rise by 2.0 percent to EUR 7,948 million (Q3 2007: EUR 7,793 million) / HealthCare and CropScience improve earning power / MaterialScience earnings significantly lower / Group EBITDA before special items down 4.2 percent to EUR 1,493 million (Q3 2007: EUR 1,559 million) / Group EBIT before special items down 6.5 percent to EUR 891 million (Q3 2007: EUR 953 million) / Full-year guidance for 2008 confirmed / Continued earnings growth predicted for 2009 » more
1:17 min.
Bayer optimistic about future business trend
Sales rise by 2.0 percent to EUR 7,948 million (Q3 2007: EUR 7,793 million) / HealthCare and CropScience improve earning power / MaterialScience earnings significantly lower / Group EBITDA before special items down 4.2 percent to EUR 1,493 million (Q3 2007: EUR 1,559 million) / Group EBIT before special items down 6.5 percent to EUR 891 million (Q3 2007: EUR 953 million) / Full-year guidance for 2008 confirmed / Continued earnings growth predicted for 2009 » more
4:01 min. 1:17 min.October 28, 2008
Dr. Andreas Resch to leave Bayer
Head of Bayer Business Services to join consulting company’s management board » more
Head of Bayer Business Services to join consulting company’s management board » more
October 17, 2008
Bayer significantly strengthens its presence in China
Startup of 350,000 tons/year MDI train / Groundbreaking for 250,000 tons/year TDI plant / Isocyanate production also to be expanded in Europe in the medium term » more
1:26 min.
Startup of 350,000 tons/year MDI train / Groundbreaking for 250,000 tons/year TDI plant / Isocyanate production also to be expanded in Europe in the medium term » more
1:26 min.October 6, 2008
Novel approach for the treatment of pulmonary hypertension
Bayer Reports Progress in Clinical Program for Riociguat
Positive Phase II Findings Reported at European Respiratory Society Meeting / Phase III Studies to Begin in 2008 » more
1:06 min.
Bayer Reports Progress in Clinical Program for Riociguat
Positive Phase II Findings Reported at European Respiratory Society Meeting / Phase III Studies to Begin in 2008 » more
1:06 min.October 1, 2008
Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care » more
1:07 min.
Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care » more
1:07 min.September 25, 2008
Bayer Schering Pharma AG
Squeeze-out entered in the Commercial Register
Squeeze-out of minority stockholders takes effect / Cash compensation of EUR 98.98 per share will be paid » more
Squeeze-out entered in the Commercial Register
Squeeze-out of minority stockholders takes effect / Cash compensation of EUR 98.98 per share will be paid » more
September 22, 2008
Bayer included once again in Carbon Disclosure Leadership Index
Bayer is one of the world's leading companies in climate protection
Board of Management member Dr. Plischke welcomes recognition of “the effort we are making through the Bayer Climate Program” / Corporate climate strategies of increasing significance to investors » more
Bayer is one of the world's leading companies in climate protection
Board of Management member Dr. Plischke welcomes recognition of “the effort we are making through the Bayer Climate Program” / Corporate climate strategies of increasing significance to investors » more
September 19, 2008
September 16, 2008
Bayer HealthCare acquires German DIREVO Biotech AG
A recognized leader in protein engineering / Expanding technological know-how in biologicals / Strengthening Bayer HealthCare’s commitment to develop innovative biologicals » more
1:15 min.
A recognized leader in protein engineering / Expanding technological know-how in biologicals / Strengthening Bayer HealthCare’s commitment to develop innovative biologicals » more
1:15 min.September 16, 2008
Venous Blood Clot Prevention after Elective Total Knee and Hip Replacement Surgery:
Bayer’s Xarelto® Approved in Canada
First approval for Bayer’s new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct Factor Xa inhibitor in the world today » more
1:13 min.
Bayer’s Xarelto® Approved in Canada
First approval for Bayer’s new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct Factor Xa inhibitor in the world today » more
1:13 min.September 4, 2008
Setting the course after a very successful first half of 2008:
Bayer CropScience plans investment of EUR 3.4 billion in research and development through 2012
Expansion of R&D program will strengthen basis for future growth / Achievement of target EBITDA margin of around 25 percent already expected in 2008 / Sales target of EUR 2 billion with new active ingredients now envisaged for 2009 / Launch of 10 new crop protection compounds with a peak sales potential of more than EUR 1 billion planned through 2012 » more
1:15 min.
Bayer CropScience plans investment of EUR 3.4 billion in research and development through 2012
Expansion of R&D program will strengthen basis for future growth / Achievement of target EBITDA margin of around 25 percent already expected in 2008 / Sales target of EUR 2 billion with new active ingredients now envisaged for 2009 / Launch of 10 new crop protection compounds with a peak sales potential of more than EUR 1 billion planned through 2012 » more
1:15 min.September 2, 2008
Bayer Submits Recombinant Human Thrombin for European Approval
Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe » more
1:01 min.
Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe » more
1:01 min.August 27, 2008
New Bayer CropScience active ingredient approved in Romania:
Thiencarbazone-methyl registered in first market
Annual sales potential of more than EUR 100 million for new corn herbicide » more
Thiencarbazone-methyl registered in first market
Annual sales potential of more than EUR 100 million for new corn herbicide » more
more News
Bookmark this page
E-mail this page
Order print version
